NasdaqGS:REGNBiotechs
Does Regeneron (REGN) Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?
Regeneron Pharmaceuticals, Inc. previously reported second-quarter 2026 revenue of US$4,290.7 million versus US$3,675.6 million a year earlier, while net income eased to US$1,296.9 million from US$1,391.6 million and diluted earnings per share from continuing operations slipped to US$12.23 from US$12.81.
At the same time, the company affirmed a quarterly dividend of US$0.94 per share payable on August 31, 2026, underscoring its willingness to return cash to shareholders even as earnings...